Halozyme Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2016. Unaudited consolidated financial statements. Halozyme develops oncology therapies and licenses its ENHANZE technology to biopharmaceutical partners; its lead proprietary candidate is PEGPH20.
Key financial results
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Total revenue | $31.9 million | $20.8 million | $107.7 million | $82.8 million |
| Operating loss | $22.7 million | $23.2 million | $60.6 million | $32.9 million |
| Net loss | $28.9 million | $24.5 million | $75.6 million | $36.5 million |
| Basic and diluted loss per share | $0.23 | $0.19 | $0.59 | $0.29 |
- Q3 revenue rose about 53%; nine-month revenue rose about 30%. Growth reflected higher royalties, bulk rHuPH20 product sales to collaborators, and research and development reimbursements.
- Royalties were $13.0 million in Q3 and $36.7 million for nine months, primarily reflecting increased Roche Herceptin SC sales. Royalties are reported one quarter after the underlying product sales.
- Research and development expense increased to $109.5 million for nine months from $65.5 million, chiefly due to PEGPH20 clinical activity and ENHANZE-related manufacturing and development. Nine-month interest expense rose to $14.4 million from $3.9 million, primarily due to the royalty-backed loan.
- The filing does not provide a single company-wide gross margin measure. Cost of product sales was $9.1 million in Q3 and $25.2 million for nine months.
- At September 30, cash and cash equivalents were $61.2 million and marketable securities were $159.8 million, totaling $221.1 million. Working capital was approximately $220 million. Cash and marketable securities totaled $108.3 million at December 31, 2015.
- Net cash used in operating activities was $34.6 million for nine months, compared with $21.9 million in 2015. Cash increased by $17.9 million over the period, supported by financing inflows.
- Reported current and long-term debt totaled approximately $212.2 million, versus approximately $49.8 million at year-end 2015. Stockholders’ equity was a deficit of $12.0 million, compared with positive equity of $43.0 million.
Material changes and outlook
- Halozyme received a $150 million royalty-backed loan in January 2016, secured by Roche and Baxalta collaboration royalties. Its September 30 balance was $157.6 million, including capitalized payment-in-kind interest and net of debt discount; the stated interest rate was 9.61%. Management estimated repayment in Q1 2020, subject to actual royalty receipts.
- In June 2016, the company entered a new senior secured loan facility with Oxford Finance and Silicon Valley Bank, drew $55 million at 8.25%, and repaid the prior facility. It may draw another $15 million in Q2 2017. The new term loan balance was $54.6 million net of discount.
- Management said existing cash, cash equivalents and marketable securities were expected to fund operations for at least 12 months. It projected cash and cash equivalents of $180–$190 million at December 31, 2016, dependent on clinical progress, manufacturing scale-up, milestones and royalties. It also said further financing may be needed and may not be available on favorable terms.
- PEGPH20 development continued in pancreatic cancer, including a Phase 3 trial begun in March 2016. Management said Study 109-202 progression-free survival data were not yet mature and reporting could move from Q4 2016 into 2017. The program carries thromboembolic-event safety risk; the filing notes a prior clinical hold and continued safety monitoring.
- Halozyme discontinued the PRIMAL PEGPH20/docetaxel study in non-small cell lung cancer in August 2016, citing recruitment and later-line enrollment, and shifted focus toward its KEYTRUDA combination study. The company also disclosed that Pfizer discontinued development of its bococizumab and rivipansel programs using ENHANZE.
- Management expected PEGPH20 research and development costs to increase and SG&A to rise moderately. Royalty revenue was generally expected to grow with collaborator product sales, but could fluctuate; collaborator-requested services and milestone-related revenue are also uncertain.
Risks, contingencies and other notable items
- Key risks include clinical efficacy and safety outcomes, regulatory approval and timing, reliance on collaborators and contract manufacturers, and the ability to sustain funding amid ongoing losses and operating cash use.
- Debt agreements impose covenants and could permit acceleration upon specified defaults. The royalty-backed loan repayment depends on Roche and Baxalta royalties; the company reported compliance with material loan covenants at quarter-end.
- The filing reported no legal proceedings that management believed would have a material adverse effect. It also reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
- The company recognized $1.3 million of Q3 and $1.6 million of nine-month income tax expense, comprising U.S. federal alternative minimum tax.
Investor verification checklist
- Track PEGPH20 Study 109-202 data timing, Phase 3 enrollment and results, and thromboembolic-event findings.
- Verify the pace and durability of Roche and Baxalta product sales and royalties, and the assumptions behind the royalty-backed loan’s estimated repayment date.
- Monitor operating cash use, the year-end cash outlook, and any need for additional financing or shareholder dilution.
- Assess whether rising research and development costs and higher interest expense are matched by sustainable revenue growth.
- Follow collaborator program decisions, manufacturing capacity and regulatory developments, including the U.S. status of Roche’s subcutaneous rituximab application.